Ency hebt ab ! - 500 Beiträge pro Seite

[kaktus10]

http://finance.yahoo.com/q?s=ENCY

Ja, denke ich auch. Hoffen wir weiter. Thelin gibt es nun in
Ireland, Deutschland, England, Australien.

Wenn die Zulassung der FDA in den USA kommt, dann geht es wirklich kräftig nach oben. DNDN war ja schon beeindruckend.

Ich bleibe fest long!

Geduld und strake Nerven sind notwendig. Zugegeben !

Gestern bereits 15% plus, heute im Pre-Market bereits 8% plus!

Frohe Ostern allerseits!

[Fruehrentner]

Antwort auf Beitrag Nr.: 28.677.194 von kaktus10 am 05.04.07 14:54:55

es gibt bereits einen thread dazu!

[trustone]

sehe ich das richtig?


am 15. Juni ist die FDA Entscheidung für die USA fällig

[kaktus10]

Ja, so ist es !

Heute kam die Zulassung in den Niederlanden:

Encysive Pharmaceuticals Announces Launch of THELIN (Sitaxentan Sodium) in the Netherlands
Monday April 16, 2:00 am ET
First Selective, Once-Daily Oral Endothelin A Receptor Antagonist Now Commercially Available for Pulmonary Arterial Hypertension Patients

HOUSTON, April 16, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals (NasdaqGM:ENCY - News) today announced the commercial availability of THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets in the Netherlands for the treatment of pulmonary arterial hypertension (PAH). The Company received European Union marketing authorization for THELIN from the European Commission in August 2006. THELIN is the first selective endothelin A receptor antagonist and the first once-daily oral treatment available for patients with PAH.

ADVERTISEMENT
click here
THELIN is indicated for improving exercise capacity in PAH patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension(3) and pulmonary hypertension associated with connective tissue disease (CTD).
``As a once-daily oral therapy, THELIN may provide PAH patients with effective symptom management in a convenient, non-invasive route of administration,'' said Anco Boonstra, M.D., Ph.D., pulmonologist, Vrije Universiteit Medical Center, Amsterdam. ``THELIN is a welcome new treatment option for patients with primary disease and also those with CTD-related PAH, where THELIN has demonstrated a therapeutic benefit.''
The European Commission's centralized licensing procedure permits Encysive to market THELIN in all 27 member states of the European Union. THELIN has been launched in three member states to date, and will be commercialized in successive EU countries as local government approval for reimbursement is obtained.